Cessatech A/S (NGM:CESSA)
Sweden · Delayed Price · Currency is SEK · Price in DKK 16.42
+0.42 (2.63%)
At close: Mar 23, 2026
Cessatech Company Description
Cessatech A/S, a pivotal-stage pediatric biotech company, develops specialty hospital medicines for children in Denmark.
Its lead candidate product is CT001, a fixed-dose nasal spray for treating acute pain in children. The company also develops CT002, a non-invasive intranasal sedation for children undergoing medical procedures in Phase 2 clinical trials; and CT003, a topical anesthetic in pre-clinical development.
Cessatech A/S was incorporated in 2020 and is based in Copenhagen, Denmark.
Cessatech A/S
| Country | Denmark |
| Founded | 2020 |
| Industry | Pharmaceutical Preparations |
| Employees | 3 |
| CEO | Jes Trygved |
Contact Details
Address: Strandvejen 60 Copenhagen, 2900 Denmark | |
| Phone | 45 93 87 23 09 |
| Website | cessatech.com |
Stock Details
| Ticker Symbol | CESSA |
| Exchange | Nordic Growth Market |
| Fiscal Year | January - December |
| Reporting Currency | DKK |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Jes Trygved | Chief Executive Officer |
| Sarah Toft Jorgensen | Chief Financial Officer |
| Sarah Toft Jorgensen | Head of Investor Relations |